Apria, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel J. Starck
- Full Time Employees
- 6,080
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 26220 Enterprise Court Lake Forest CA United States of America 46237
- IPO Date
- Feb 11, 2021
- CIK
- 0001735803
- Website
- apria.com
- Similar Companies
- Business
- Apria, Inc. (NYSE:APR) provides integrated home healthcare equipment and related services across the United States; core offerings include home respiratory therapies such as stationary and portable oxygen equipment and non-invasive ventilators, obstructive sleep apnea treatments comprising continuous positive airway pressure and bi-level positive airway pressure devices with patient support services, negative pressure wound therapy products and supplies, comprehensive COPD care programs, sleep management services and products, homecare pharmacy services specializing in respiratory medications through Apria Pharmacy Network, and additional home medical equipment for chronic and non-chronic conditions including diabetes care via continuous glucose monitors and insulin pumps. The company operates 272 branches nationwide, serves approximately 2 million patients annually with 6,500 team members, and maintains a focus on high-touch clinical support bridging acute care to home settings for patients, providers, and payors. Founded in 1995 through the merger of Homedco Group and Abbey Healthcare Group and headquartered in Indianapolis, Indiana, ApriaDirect provides these services to a broad base of insured healthcare customers. In March 2022, Owens & Minor, Inc. completed its $1.6 billion acquisition of Apria, integrating it with the Byram Healthcare business to form the Patient Direct segment, thereby expanding product portfolios in home health, diversifying revenue streams, and strengthening market position in the growing sector. Recent financial performance reflects resilience with trailing twelve-month non-GAAP earnings per share of $1.75 and quarterly revenue around $287-296 million, alongside analyst price targets near $39 amid ongoing operations under Owens & Minor.
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
NetworkNews Audio Announces Audio Press Release (APR) Discussing Solutions to Core Limitation of Mass Drone Warfare
Automotive Properties Real Estate Investment Trust (APR.UN:CA) Q1 2026 Earnings Call Transcript
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways
NetworkNews Audio Announces Audio Press Release (APR) Discussing Software-Only Solutions to GPS-Denied Navigation Systems
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Automotive Properties Real Estate Investment Trust (APR.UN:CA) Q4 2025 Earnings Call Transcript
NetworkNews Audio Announces Audio Press Release (APR) Discussing AI Robotics Companies Scaling Beyond Prototype Phase into Commercialization
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
NetworkNews Audio Announces Audio Press Release (APR) Discussing Launch of New Platform Designed to Solve ‘Intent Gap' Bottleneck
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
Is Beyond Meat a Long-Term Buy or a Fad That's Fading?
Automotive Properties Real Estate Investment Trust (APR.UN:CA) Q3 2025 Earnings Call Transcript
NetworkNewsAudio Announces Audio Press Release (APR) on Fully Permitted, Funded Junior Miner Project
NetworkNewsAudio Announces Audio Press Release (APR) on Emerging Junior with High-Quality Mill, Mineral Project
NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets